§ 314.445  
(4) Oxygen carriers.

§ 314.445  Guidance documents.  
(a) FDA has made available guidance documents under § 10.115 of this chapter to help you to comply with certain requirements of this part.  
(b) The Center for Drug Evaluation and Research (CDER) maintains a list of guidance documents that apply to CDER’s regulations. The list is maintained on the Internet and is published annually in the FEDERAL REGISTER. A request for a copy of the CDER list should be directed to the Office of Training and Communications, Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002.

§ 314.500  Scope.  
This subpart applies to certain new drug products that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit to patients over existing treatments (e.g., ability to treat patients unresponsive to, or intolerant of, available therapy, or improved patient response over available therapy).

§ 314.510  Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.  
FDA may grant marketing approval for a new drug product on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. Approval under this section will be subject to the requirement that the applicant study the drug further, to verify and describe its clinical benefit, where there is uncertainty as to the relation of the surrogate endpoint to clinical benefit, or of the observed clinical benefit to ultimate outcome. Postmarketing studies would usually be studies already underway. When required to be conducted, such studies must also be adequate and well-controlled. The applicant shall carry out any such studies with due diligence.

§ 314.520  Approval with restrictions to assure safe use.  
(a) If FDA concludes that a drug product shown to be effective can be safely used only if distribution or use is restricted, FDA will require such postmarketing restrictions as are needed to assure safe use of the drug product, such as:  
(1) Distribution restricted to certain facilities or physicians with special training or experience; or  
(2) Distribution conditioned on the performance of specified medical procedures.  
(b) The limitations imposed will be commensurate with the specific safety concerns presented by the drug product.

§ 314.530  Withdrawal procedures.  
(a) For new drugs approved under §§314.510 and 314.520, FDA may withdraw approval, following a hearing as provided in part 15 of this chapter, as modified by this section, if:  
(1) A postmarketing clinical study fails to verify clinical benefit;  
(2) The applicant fails to perform the required postmarketing study with due diligence;  
(3) Use after marketing demonstrates that postmarketing restrictions are inadequate to assure safe use of the drug product;